Liver Metastases

Oncology
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AdecatumumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00866944Completed35Est. Nov 2011
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
gemcitabine hydrochloridePhase 1/21 trial
Active Trials
NCT00645710CompletedEst. Feb 2018
Alpha Tau Medical
Alpha Tau MedicalJERUSALEM, Israel
1 program
Diffusing Alpha Radiation Emitters TherapyN/A1 trial
Active Trials
NCT05829291Recruiting10Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenAdecatumumab
City Therapeuticsgemcitabine hydrochloride
Alpha Tau MedicalDiffusing Alpha Radiation Emitters Therapy

Clinical Trials (3)

Total enrollment: 45 patients across 3 trials

NCT00866944AmgenAdecatumumab

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

Start: Mar 2009Est. completion: Nov 201135 patients
Phase 2Completed
NCT00645710City Therapeuticsgemcitabine hydrochloride

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Start: Feb 2005Est. completion: Feb 2018
Phase 1/2Completed
NCT05829291Alpha Tau MedicalDiffusing Alpha Radiation Emitters Therapy

Alpha Radiation Emitters Device for the Treatment of Liver Metastases (DaRT)

Start: Oct 2023Est. completion: Feb 202610 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 45 patients
3 companies competing in this space